相关临床试验
39
8 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1996
进行中（未招募）
5
12.8%
已完成
25
64.1%
Enrolling By Invitation
1
2.6%
尚未招募
2
5.1%
招募中
4
10.3%
Unknown
1
2.6%
撤回
1
2.6%
暂无批准数据
- A promising rVSV-based vaccine against the Bundibugyo strain of Ebola, developed by Thomas Geisbert in 2011, has never entered human trials due to lack of funding and commercial interest. - The current outbreak in the DRC and Uganda has infected hundreds and killed around 200 people, prompting WHO to identify Geisbert's candidate as the most promising option. - CEPI has offered up to $3.2 million to prepare and start testing manufacturing materials, with prior rVSV safety data potentially expediting regulatory approval pathways. - Scientists have been unable to obtain a live virus sample from the current outbreak, and the ~2% genetic difference from previous strains presents a risk the vaccine may not be as effective.
- The WHO has prioritized three experimental treatments—MBP134, maftivimab, and remdesivir—for the Bundibugyo strain of Ebola, with clinical trials set to begin in the DRC. - Africa CDC has issued an urgent appeal for $18 million to support therapeutic trials, warning that funding shortfalls could delay life-saving research. - Among vaccines, the rVSV Bundibugyo candidate from IAVI is considered most promising but remains 7–9 months from trial readiness, while ChAdOx1 Bundibugyo could be available in 2–3 months. - No approved vaccines or therapies currently exist specifically for Bundibugyo virus disease, underscoring the critical unmet medical need.
- Researchers developed an accelerated manufacturing platform using transient electroporation and immunoaffinity purification that reduces HIV vaccine production timelines from 12 months to 4 months while cutting costs by over $500,000. - The platform successfully produced three HIV envelope proteins at 50-80L scale with gram-level yields suitable for Phase I clinical studies, including a stabilized 16055 DG4 NFL trimer currently in human trials. - Comprehensive characterization confirmed the manufactured trimers maintain native-like structure and elicit neutralizing antibodies in preclinical studies, validating this approach for rapid HIV vaccine candidate evaluation.
- Turn Therapeutics has demonstrated 100% recovery of vesicular stomatitis virus (VSV) after 72 hours in an oil-based carrier at room temperature, potentially eliminating cold storage requirements for vaccines. - The breakthrough, developed in partnership with the International AIDS Vaccine Initiative, represents the first successful quantitative recovery of a live virus stably suspended in an oil-based carrier. - This technology could revolutionize vaccine distribution to remote and low-resource settings by extending viability from four hours to at least 72 hours without refrigeration.
- The US Agency for International Development (USAID) has suspended all foreign assistance funding, forcing the pause of multiple clinical trials and threatening ongoing research in HIV, tuberculosis, and malaria. - Non-profit organizations like International AIDS Vaccine Initiative (IAVI) have already halted trials, while existing study participants face uncertainty about continued care and follow-up. - Experts warn that the sudden funding gap could lead to increased antimicrobial resistance, setbacks in global health initiatives, and extended drug development timelines unless other sponsors and foundations step in.
